Add time:09/09/2019 Source:sciencedirect.com
Aim:To evaluate the efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist, in the subgroup of older patients from a pooled analysis of three phase III, multicentre, randomized, double-blind clinical trials in patients with overactive bladder (OAB).
We also recommend Trading Suppliers and Manufacturers of Darifenacin (cas 133099-04-4). Pls Click Website Link as below: cas 133099-04-4 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View